Onxeo S.A. buy metanicnor
Summary
This prediction ended on 15.09.16 with a price of €3.14. With a performance of -2.79%, the BUY prediction for Onxeo S.A. by metanicnor closed slightly in the red. metanicnor has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Onxeo S.A. | -2.698% | -2.698% | -64.984% | -84.782% |
| iShares Core DAX® | -0.870% | -1.700% | 10.560% | 13.129% |
| iShares Nasdaq 100 | -5.561% | -3.604% | 34.335% | 39.856% |
| iShares Nikkei 225® | -6.138% | -7.732% | 16.215% | 0.044% |
| iShares S&P 500 | -3.141% | -2.011% | 24.534% | 39.859% |
Comments by metanicnor for this prediction
In the thread Onxeo S.A. diskutieren
onxeo
la biotech la plus avancée en france mais seulement 131 M€ de capitalisation : onxeo vend 3 médicaments : Beleodaq, Sitavig, & Loramyc
onxeo va racheter DNA Therapeutics
Onxeo ne lancera pas seul une phase III sur Validive
à fin decembre 2016, la trésorerie se monte à 33.8 M€ donc la prochaine levée de fonds devrait être mi-2017
les 1ers résultats de la phase III de Livatag devraient tomber début 2017
aurgalys vise 11.12 €
cm cic securities vise 10.2 €
edison vise 8,3 €
Invest Securities vise 8 €
investir vise 11€ depuis le 4/08/2014
oddo vise 9 €